1.03
price down icon8.85%   -0.10
after-market Dopo l'orario di chiusura: 1.01 -0.02 -1.94%
loading
Precedente Chiudi:
$1.13
Aprire:
$1.07
Volume 24 ore:
326.15K
Relative Volume:
0.40
Capitalizzazione di mercato:
$4.39M
Reddito:
-
Utile/perdita netta:
$-6.78M
Rapporto P/E:
-0.0241
EPS:
-42.6996
Flusso di cassa netto:
$-4.67M
1 W Prestazione:
+1.98%
1M Prestazione:
+14.62%
6M Prestazione:
-29.93%
1 anno Prestazione:
-37.95%
Intervallo 1D:
Value
$1.00
$1.12
Intervallo di 1 settimana:
Value
$0.98
$1.25
Portata 52W:
Value
$0.80
$2.18

Clearmind Medicine Inc Stock (CMND) Company Profile

Name
Nome
Clearmind Medicine Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
CMND's Discussions on Twitter

Confronta CMND con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CMND
Clearmind Medicine Inc
1.03 6.08M 0 -6.78M -4.67M -42.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Clearmind Medicine Inc Borsa (CMND) Ultime notizie

pulisher
Jul 23, 2025

What analysts say about Clearmind Medicine Inc. stockPowerful growth strategies - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Clearmind Medicine Inc Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder - MarketScreener

Jul 23, 2025
pulisher
Jul 23, 2025

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder - The Manila Times

Jul 23, 2025
pulisher
Jul 23, 2025

Clearmind advances AUD treatment with new trial site in Tel Aviv - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

Clearmind Medicine Inc. Announces Successful Site Initiation for Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center - Nasdaq

Jul 23, 2025
pulisher
Jul 22, 2025

Is Clearmind Medicine Inc. a good long term investmentGame-changing returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Clearmind Medicine Inc. stock priceOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Clearmind Medicine Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Clearmind Medicine Surges 18.99%: What's Fueling This Volatile Biotech Rally? - AInvest

Jul 21, 2025
pulisher
Jul 20, 2025

How Clearmind Medicine Inc. stock reacts to Fed policy changesFree Access to Community with 300% Return - beatles.ru

Jul 20, 2025
pulisher
Jul 16, 2025

What makes Clearmind Medicine Inc. stock price move sharplySmart Money Trade Setups - beatles.ru

Jul 16, 2025
pulisher
Jul 16, 2025

Clearmind Expands its Clinical Trial for Alcohol Use, New Site Activated and Additional Participant Enrolled - MarketScreener

Jul 16, 2025
pulisher
Jul 15, 2025

How Clearmind Medicine Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Clearmind Medicine Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Clearmind Expands Its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Clearmind expands phase I/IIa trial for alcohol use disorder treatment By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Clearmind expands phase I/IIa trial for alcohol use disorder treatment - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 to Johns Hopkins University to Address Alcohol Use Disorder - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - The Manila Times

Jul 15, 2025
pulisher
Jul 09, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Up 4.5% – Here’s Why - Defense World

Jul 09, 2025
pulisher
Jul 09, 2025

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Yahoo Finance

Jul 09, 2025
pulisher
Jul 04, 2025

Clearmind Medicine Soars 32.89% on Clinical Trial Approval - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

CMND’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - Nasdaq

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind’s Stock Gains Momentum with New Trial Expansions - timothysykes.com

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind Medicine’s Rise: What’s Steering the Surge? - timothysykes.com

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind receives IRB approval for alcohol disorder treatment trial - Investing.com

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind receives IRB approval for alcohol disorder treatment trial By Investing.com - Investing.com South Africa

Jul 03, 2025
pulisher
Jul 03, 2025

Clearmind Medicine Inc. Receives IRB Approval for Phase 1/2a Clinical Trial of CMND-100 for Alcohol Use Disorder - Nasdaq

Jul 03, 2025
pulisher
Jun 30, 2025

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder - The Manila Times

Jun 30, 2025
pulisher
Jun 30, 2025

Clearmind doses first participant in alcohol disorder treatment trial - Investing.com

Jun 30, 2025

Clearmind Medicine Inc Azioni (CMND) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):